Tags

Type your tag names separated by a space and hit enter

Review of clinical experience in the United States with cefpodoxime proxetil in adults with uncomplicated urinary tract infections.
Drugs. 1991; 42 Suppl 3:41-50.D

Abstract

Two controlled United States trials compared the safety and efficacy of cefpodoxime proxetil (100mg twice daily) with either cefaclor (250mg 3 times daily) or amoxicillin (250mg 3 times daily) in patients with uncomplicated urinary tract infections. Treatment duration was 7 days. 307 of 762 patients treated with cefpodoxime proxetil, 99 of 190 treated with cefaclor, and 57 of 185 treated with amoxicillin were evaluable for efficacy. 311, 99 and 59 pathogens were isolated from cefpodoxime proxetil, cefaclor and amoxicillin patients, respectively, the most common pathogens being Escherichia coli, Klebsiella spp., Proteus mirabilis, and Staphylococcus saprophyticus. Bacteriological cure rates were 80% (247/307), 82% (81/99) and 70% (40/57) for cefpodoxime proxetil, cefaclor and amoxicillin, respectively. Respective clinical cure rates were 79% (242/307), 79% (78/99) and 72% (41/57). Cefpodoxime proxetil was well tolerated, and there was no significant difference between the groups in the overall incidence of adverse experiences. Thus, cefpodoxime proxetil is efficacious and safe in the treatment of patients with uncomplicated urinary tract infections and compares favourably with cefaclor and amoxicillin.

Authors+Show Affiliations

University of Tennessee, Memphis.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

1726207

Citation

Cox, C E., et al. "Review of Clinical Experience in the United States With Cefpodoxime Proxetil in Adults With Uncomplicated Urinary Tract Infections." Drugs, vol. 42 Suppl 3, 1991, pp. 41-50.
Cox CE, Graveline JF, Luongo JM. Review of clinical experience in the United States with cefpodoxime proxetil in adults with uncomplicated urinary tract infections. Drugs. 1991;42 Suppl 3:41-50.
Cox, C. E., Graveline, J. F., & Luongo, J. M. (1991). Review of clinical experience in the United States with cefpodoxime proxetil in adults with uncomplicated urinary tract infections. Drugs, 42 Suppl 3, 41-50.
Cox CE, Graveline JF, Luongo JM. Review of Clinical Experience in the United States With Cefpodoxime Proxetil in Adults With Uncomplicated Urinary Tract Infections. Drugs. 1991;42 Suppl 3:41-50. PubMed PMID: 1726207.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Review of clinical experience in the United States with cefpodoxime proxetil in adults with uncomplicated urinary tract infections. AU - Cox,C E, AU - Graveline,J F, AU - Luongo,J M, PY - 1991/1/1/pubmed PY - 1991/1/1/medline PY - 1991/1/1/entrez SP - 41 EP - 50 JF - Drugs JO - Drugs VL - 42 Suppl 3 N2 - Two controlled United States trials compared the safety and efficacy of cefpodoxime proxetil (100mg twice daily) with either cefaclor (250mg 3 times daily) or amoxicillin (250mg 3 times daily) in patients with uncomplicated urinary tract infections. Treatment duration was 7 days. 307 of 762 patients treated with cefpodoxime proxetil, 99 of 190 treated with cefaclor, and 57 of 185 treated with amoxicillin were evaluable for efficacy. 311, 99 and 59 pathogens were isolated from cefpodoxime proxetil, cefaclor and amoxicillin patients, respectively, the most common pathogens being Escherichia coli, Klebsiella spp., Proteus mirabilis, and Staphylococcus saprophyticus. Bacteriological cure rates were 80% (247/307), 82% (81/99) and 70% (40/57) for cefpodoxime proxetil, cefaclor and amoxicillin, respectively. Respective clinical cure rates were 79% (242/307), 79% (78/99) and 72% (41/57). Cefpodoxime proxetil was well tolerated, and there was no significant difference between the groups in the overall incidence of adverse experiences. Thus, cefpodoxime proxetil is efficacious and safe in the treatment of patients with uncomplicated urinary tract infections and compares favourably with cefaclor and amoxicillin. SN - 0012-6667 UR - https://www.unboundmedicine.com/medline/citation/1726207/Review_of_clinical_experience_in_the_United_States_with_cefpodoxime_proxetil_in_adults_with_uncomplicated_urinary_tract_infections_ L2 - https://dx.doi.org/10.2165/00003495-199100423-00009 DB - PRIME DP - Unbound Medicine ER -